BioLife Solutions, Inc.
BLFS
$20.12
-$0.55-2.66%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 63.91% | 31.21% | 28.94% | 29.88% | 346.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 63.91% | 31.21% | 28.94% | 29.88% | 346.18% |
| Cost of Revenue | 107.77% | 37.11% | 38.11% | 31.70% | 129.54% |
| Gross Profit | 45.59% | 28.09% | 24.43% | 28.96% | 19.34% |
| SG&A Expenses | 2.37% | 23.40% | 19.72% | 10.37% | 131.79% |
| Depreciation & Amortization | 103.69% | 2.34% | 3.66% | 2.03% | -191.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 70.56% | 29.10% | 26.27% | 15.79% | 267.29% |
| Operating Income | -114.76% | 78.71% | 14.09% | 63.03% | -78.91% |
| Income Before Tax | 312.58% | 227.59% | -182.64% | 86.36% | -95.87% |
| Income Tax Expenses | -820.83% | 202.50% | 12,500.00% | -17.65% | 110.30% |
| Earnings from Continuing Operations | 373.71% | 231.85% | -184.86% | 86.00% | -96.16% |
| Earnings from Discontinued Operations | -25.41% | -- | -- | -- | 145.25% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.16% | 136.47% | 23.56% | 95.62% | 183.30% |
| EBIT | -114.76% | 78.71% | 14.09% | 63.03% | -78.91% |
| EBITDA | -77.47% | -34.39% | -75.38% | 116.32% | -54.65% |
| EPS Basic | -13.93% | 135.23% | 26.42% | 95.78% | 180.04% |
| Normalized Basic EPS | 298.41% | 222.67% | 87.62% | 86.76% | -82.88% |
| EPS Diluted | -13.94% | 127.10% | 26.42% | 95.78% | 177.58% |
| Normalized Diluted EPS | 304.92% | 220.00% | 87.62% | 86.76% | -83.42% |
| Average Basic Shares Outstanding | 3.21% | 3.79% | 3.90% | 3.75% | 4.07% |
| Average Diluted Shares Outstanding | 2.03% | 5.52% | 3.90% | 3.75% | 7.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |